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A B S T R A C T
Pseudoexfoliation syndrome (PEXS) is an age-related elastosis, strongly associated with the development of
secondary glaucoma. It is clearly suggested that PEXS has a genetic component, but this has not been extensively
studied. Here, a genome-wide association study (GWAS) using a DNA-pooling approach was conducted to ex-
plore the potential association of genetic variants with PEXS in a Polish population, including 103 PEXS patients
without glaucoma and 106 perfectly (age- and gender-) matched controls. Individual sample TaqMan genotyping
was used to validate GWAS-selected single-nucleotide polymorphism (SNP) associations. Multivariate binary
logistic regression analysis was applied to develop a prediction model for PEXS. In total, 15 SNPs representing
independent PEXS susceptibility loci were selected for further validation in individual samples. For 14 of these
variants, signiﬁcant diﬀerences in the allele and genotype frequencies between cases and controls were iden-
tiﬁed, of which 12 remained signiﬁcant after Benjamini–Hochberg adjustment. The minor allele of ﬁve SNPs was
associated with an increased risk of PEXS development, while for nine SNPs, it showed a protective eﬀect.
Beyond the known LOXL1 variant rs2165241, nine other SNPs were located within gene regions, including in
OR11L1, CD80, TNIK, CADM2, SORBS2, RNF180, FGF14, FMN1, and RBFOX1 genes. None of these associations
with PEXS has previously been reported. Selected SNPs were found to explain nearly 69% of the total risk of
PEXS development. The overall risk prediction accuracy for PEXS, expressed by the area under the ROC curve
(AUC) value, increased by 0.218, from 0.672 for LOXL1 rs2165241 alone to 0.89 when seven additional SNPs
were included in the proposed 8-SNP prediction model. In conclusion, several new susceptibility loci for PEXS
without glaucoma suggested that neuronal development and actin remodeling are potentially involved in either
PEXS onset or inhibition or delay of its conversion to glaucoma.
1. Introduction
Pseudoexfoliation syndrome (PEXS) is an age-related disorder in
which ﬁbrillogranular aggregates (PEX material) are progressively de-
posited at abnormally high concentrations in the extracellular matrix
(ECM) (Ovodenko et al., 2007). PEX material was primarily recognized
in the intraocular tissues, where it is commonly visible in the form of
concentric circles at the pupillary margin and anterior lens capsule, but
may also be observed at the iridocorneal angle, zonules, ciliary pro-
cesses, and other parts of the eye (Ritch and Schlötzer-Schrehardt,
2001). PEXS is now considered to be a systemic disease, in which the
eye is merely one of the aﬀected organs (Streeten et al., 1992). PEX
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material may also be produced in the skin, lungs, liver, and other
visceral organs and its presence was shown to be associated with var-
ious diseases outside the eyes, such as coronary artery disease, hearing
loss, and Alzheimer's disease.
PEXS is the most common identiﬁable cause of secondary open-
angle glaucoma (OAG), accounting for about 25% of all OAG cases
worldwide (Ritch and Schlötzer-Schrehardt, 2001). The estimated 15-
year risk of PEXS conversion to pseudoexfoliation glaucoma (PEXG) is
up to 60% (Benitez-del-Castillo Sanchez et al., 2015; Jeng et al., 2007).
Compared with primary OAG, PEXG is characterized by rapid pro-
gression of glaucomatous optic nerve damage, usually more advanced
visual ﬁeld loss at diagnosis, and overall worse prognosis, as well as
poorer medical therapy outcomes, both conservative and surgical
(Ritch, 2001). The deposition of PEX material in the trabecular mesh-
work causes resistance to the outﬂow of aqueous humor, which corre-
lates with higher levels of intraocular pressure (IOP) and increased
severity of optic neuropathy (Gottanka et al., 1997; Schlötzer-
Schrehardt and Naumann, 1995), partly explaining the more aggressive
clinical course of PEXG.
A higher risk of mature and nuclear cataract and serious intra- and
postoperative complications of cataract surgery is another important
clinical consequence of PEXS (Conway et al., 2004; Ritch, 2001). Early
cataract surgery is especially advisable in PEXS patients, since apart
from the improvement in visual acuity, the lens is removed, which is
one of the possible sources of PEX material (Merkur et al., 2001). In
addition, the risk of therapy complications is lower in early stages of
PEXS, when no severe zonulopathy or nuclear sclerosis has yet devel-
oped. Unfortunately, the current diagnosis of PEXS is based on a slit
lamp examination, by which the typical deposits are detectable only at
advanced stages of the disease, while complications of the syndrome
and irreversible damage to some part of the optic nerve may already
have occurred at the preclinical stage.
PEXS is a late-onset disorder aﬀecting about 10–20% of the general
population over the age of 60 (Forsius et al., 2002; Ringvold, 1999). It is
more common in women than in men (Jonasson, 2009). Although PEXS
occurs worldwide, the incidence of the syndrome varies widely among
diﬀerent ethnic groups, which is suggested mainly to be related to the
variation in their genetic backgrounds (Challa, 2009; Schlötzer-
Schrehardt, 2011). The etiology of PEXS remains poorly understood,
but the higher risk of the disease in certain ethnic groups, along with
strong familial disease aggregation, clearly indicates that genetic fac-
tors have a strong inﬂuence on its development. Nonetheless, a simple
inheritance pattern of the disease is not evident, implying that an in-
terplay of several genes and/or environmental factors lies behind this
condition (Damji et al., 1998).
The lysyl oxidase-like 1 (LOXL1) gene is the most important genetic
risk factor for both PEXS and PEXG identiﬁed to date; there is a strong
biochemical rationale for its involvement in the development of these
diseases. The protein that it encodes is an extracellular copper-depen-
dent enzyme that catalyzes the oxidative deamination of lysine residues
of tropoelastin, the ﬁrst step in the formation of elastic ﬁbers, which are
considered a major constituent of PEX material (Thomassin et al., 2005;
Wagenseil and Mecham, 2007). Impaired tissue expression or function
of LOXL1 contributes to the abnormal elastic ﬁber production (Lee,
2008). In addition, LOXL1 itself was found to be present in PEX ma-
terial and to colocalize with elastic ﬁber components such as elastin,
ﬁbrillin-1, and ﬁbulin-4, the expression of which in anterior eye tissues
is regulated in accordance with the expression of LOXL1 (Zenkel and
Schlötzer-Schrehardt, 2014).
The strong association between PEXS/PEXG and LOXL1 gene var-
iants was ﬁrst discovered by a genome-wide association study (GWAS)
in Swedish and Icelandic individuals (Thorleifsson et al., 2007). This
involved three single-nucleotide polymorphisms (SNPs): rs2165241,
located within the ﬁrst intron, and two nonsynonymous SNPs,
rs1048661 (R141L) and rs3825942 (G153D), in the ﬁrst exon. It re-
mains unclear whether these two coding variants can eﬃciently aﬀect
LOXL1 expression (Schlötzer-Schrehardt et al., 2012; Wiggs and
Pasquale, 2014), but some recent ﬁndings suggest they can be critical
for catalytic activation of the enzyme and substrate binding (Sharma
et al., 2016; Thomassin et al., 2005). A link between PEXS and the
LOXL1 locus was further conﬁrmed in many other populations world-
wide, but the reported results are somewhat controversial and incon-
clusive (Álvarez et al., 2015; Aung et al., 2015; Challa, 2009; Jonasson,
2009; Malukiewicz et al., 2011). Surprisingly, the particular allele of
some SNPs associated with increased disease risk was frequently re-
versed depending on the ethnic group studied (Founti et al., 2015).
Additionally, the risk-associated LOXL1 variants are usually present at a
high frequency in the general population, showing that most people
who carry a high-risk allele do not develop PEXS. Recently, a protective
rare variant rs201011613 (Y407F) of LOXL1 was identiﬁed by deep
sequencing of the entire gene (Aung et al., 2017). This variant was
predicted to aﬀect LOXL1 function, however, it was found exclusively
in the Japanese population. These ﬁndings strongly suggest that there
are additional genes, environmental factors, or epigenetic events that
modify the susceptibility to PEXS.
Some evidence for the presence of genetic risk factors other than
LOXL1 variants was provided by a genome-wide scan carried out on a
large Finnish family, indicating an association of PEXS with loci at
18q12.1–21.33 (Lemmelä et al., 2007). Two more recent GWASs
identiﬁed additional PEXS susceptibility loci at the contactin-associated
protein-like 2 (CNTNAP2) gene (Krumbiegel et al., 2011) and the vol-
tage-gated Ca2+ channel subunit α1A (CACNA1A) gene (Aung et al.,
2015). In addition, several candidate genes, such as those encoding
clusterin (CLU), apolipoprotein E (APOE), tumor necrosis factor (TNF)-
α, matrix metalloproteinases (MMPs), and latent transforming growth
factor (TGF)-β binding protein 2 (LTBP2), were suggested to be linked
to PEXS/PEXG; however, besides the LOXL1 locus, to date only poly-
morphisms in CLU and CNTNAP2 have been associated with the disease
in diﬀerent populations (Aboobakar and Allingham, 2014; Krumbiegel
et al., 2009).
In the DNA-pooling GWAS described here, we particularly focused
on the appropriate establishment of patient and control groups, limiting
the possibility of misclassiﬁcation. Moreover, to increase the homo-
geneity of the case cohort, only patients with PEXS without glaucoma
were included. Our methodological approach enabled the detection of
several new variants associated with PEXS, in addition to LOXL1. Based
on them, a prediction model for PEXS was proposed. The identiﬁed
associations suggest that processes such as neuronal development, sy-
napse organization, and synaptic transmission, as well as actin cytos-
keleton remodeling, contribute to PEXS.
2. Materials and methods
2.1. Ethics statement
All enrolled patients and control subjects were Polish Caucasians
recruited at the Department of Ophthalmology, Centre of Postgraduate
Medical Education in Warsaw, Poland, between mid-2012 and mid-
2014. The local ethics committee approved the study (No. 48/PW/
2011) and all participants provided written informed consent. The
study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki.
2.2. Patients
The study included 209 individuals (149 females and 60 males): 103
with PEXS and 106 perfectly age- and sex-matched healthy controls.
Demographic characteristics of the patients and controls are shown in
Table 1. All subjects underwent a detailed ophthalmologic examination,
including ocular and medical history, distance and near visual acuity
(Snellen charts), slit lamp biomicroscopy, Goldmann applanation to-
nometry, gonioscopy, and dilated fundoscopy. Additionally, automated
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perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss
Meditec AG, Germany) using the SITA Standard 30-2 test. Measurement
of retinal nerve ﬁber layer thickness was performed by spectral domain
optical coherence tomography (OCT) using 3D OCT-1000 (Topcon
Medical Systems, USA). All assessments were performed by a single
ophthalmologist (KZ). Patients with any evidence of glaucomatous
optic neuropathy in either eye were excluded from both the control and
the PEXS groups. All patients had IOP<21mmHg in both eyes. PEXS
was proven by the presence of typical PEX material at the papillary
margin and/or on the anterior lens capsule in at least one eye, during
slit lamp examination after pupil dilation. The presence of corneal or
posterior segment pathologies was an exclusion criterion.
2.3. Genome-wide microarray allelotyping
A pooled-DNA sample-based GWAS was performed as described
previously (Gaj et al., 2012). Genomic DNA was extracted from whole
blood treated with EDTA using a QIAamp DNA Mini Kit (Qiagen, Ger-
many), quantiﬁed using a Quant-iT™ PicoGreen dsDNA Kit (Invitrogen,
UK), and checked on 1% agarose gel for integrity. DNA samples that
passed quality control tests were combined according to diagnosis and
gender at equimolar concentrations to obtain 10-DNA sample pools. A
total of 10 DNA pools were prepared for each of the two groups (control
and PEXS), seven for women and three for men. Pooled-DNA samples
were adjusted to a ﬁnal concentration of 50 ng/μl in Tris-EDTA buﬀer
(pH=8) and analyzed individually on Illumina Human Omni2.5-
Exome BeadChips by a commercial organization (AROS Appl. Biotech.,
Aarhus N, Denmark). GWAS datasets from this study are available at
the GEO database under GSE93205.
2.4. Individual genotyping
For the validation of GWAS ﬁndings, the loci represented by blocks
of SNPs associated with disease at the p < 5×10−3, for which the
interval between all pairs of adjacent SNPs was less than 30 kb, were
taken into consideration. One index SNP from each of the identiﬁed
loci, associating at p < 10−4, was selected for further validation with
individual PEXS and control samples, using the TaqMan SNP
Genotyping Assays (Thermo Fisher, USA), SensiMix™ II Probe Kit
(Bioline Ltd., UK), and a 7900HT Real-Time PCR system (Thermo
Fisher, USA) in a 384-well format.
2.5. Statistical analyses
2.5.1. Clinical data
For the comparison of clinical data between patients with PEXS and
control subjects, the Mann–Whitney–Wilcoxon test was used. The p-
values were adjusted for multiple comparisons using the
Benjamini–Hochberg algorithm (Benjamini and Hochberg, 1995) and
adjusted p-values of less than 0.05 were considered signiﬁcant.
2.5.2. Genome-wide allelotyping
The intensity of each SNP was calculated as the relative allele signal
(RAS) for each microarray, as described previously (Gaj et al., 2012).
The RAS was used as an approximation of the allele ratio. Student's t-
test (Welch variant) was used to compare allele ratios between groups.
Owing to a lack of the call-rate statistic for pooled samples, quality was
assessed by visual inspection of the ﬁrst two principal components.
Principal component analysis (PCA) revealed no outliers (Fig. S1). Po-
pulation heterogeneity was further assessed with quantile-guantile (Q-
Q) plot (Fig. S2). To calculate lambda, p-values from Student's t-test
were converted to chi-square values. Lambda value was of 1.06 and
together with Q-Q plot raised no concerns regarding population
homogeneity. Probes with missing signal reads were removed. Calcu-
lations were performed using the statistical software package R version
3.1.1 (R: The R Project for Statistical Computing).
2.5.3. Individual genotyping
Based on microarray analysis, SNPs potentially associated with
PEXS were selected for validation using the TaqMan SNP Genotyping
Assay and individual DNA samples. The Hardy–Weinberg equilibrium
and associations were examined using the chi-square test implemented
in the R package. The odds ratio (OR) and 95% conﬁdence interval (CI)
were estimated by normal approximation implemented in the EpiTools
R package (CRAN - Package epitools). The Benjamini–Hochberg algo-
rithm was used to adjust the p-value signiﬁcance threshold for multiple
comparisons (Benjamini and Hochberg, 1995). The study power cal-
culations were performed with the “pwr” package (CRAN - Package
pwr), assuming equal groups of 100 samples and baseline allele fre-
quencies of 0.05, 0.1, 0.2, and 0.5 (Table S1). Calculations were per-
formed for a signiﬁcance threshold equal to 0.05.
2.5.4. Prediction modeling
Prediction analysis was performed using the binary logistic regres-
sion method and PS IMAGO 4 software (IBM SPSS Statistics 24). The
prediction model was constructed using the full set of samples minus
those with missing data, giving a ﬁnal number of 193. To evaluate the
performance of the model, a 10-fold cross-validation procedure was
applied, as described previously (Hastie et al., 2009; Pośpiech et al.,
2015). For this purpose, the entire set of samples was split randomly
into 10 equinumerous parts indexed by k (k=1, 2, …, 10). For each k,
the kth part was excluded and the model was developed using samples
from the other k−1 parts. Then, the prediction parameters for every k
were calculated on the excluded kth part of the samples. The ﬁnal
prediction parameters were estimated based on 10 models built in the
cross-validation procedure (Hastie et al., 2009).
At ﬁrst, multivariate binary logistic regression enabling simulta-
neous testing of all of the variables was conducted to adjust the asso-
ciation results for all other predictors and ﬁnally to select SNPs with
independent eﬀects. The selected SNPs were then ranked according to
their p-values and sequentially introduced into the model to test their
impact on prediction accuracy. The probability of disease development
for every tested sample was assigned and then used to calculate pre-
diction parameters, including the area under the curve (AUC), sensi-
tivity, speciﬁcity, positive predictive value (PPV), and negative pre-
dictive value (NPV) (Pośpiech et al., 2012). DNA variants that increased
AUC value by at least 0.01 were included in the ﬁnal prediction model.
The remaining parameters describing accuracy of prediction were then
calculated using two probability threshold levels: 50% and 70%. A
probability threshold of 50% means that PEXS was predicted if the
prediction probability was ≥50%. If the probability was calculated to
be<50% then a no-PEXS stage was predicted. A probability threshold
of 70% means that PEXS was predicted only if the prediction prob-
ability was ≥70%. Prediction results that did not reach the 70%
probability threshold were considered to be inconclusive (30%–70%) or
no-PEXS (< 30%) (Pośpiech et al., 2015; Walsh et al., 2011). The
proportion of overall risk of PEXS development explained by the tested
variants was estimated using the Nagelkerke pseudo-R2 statistic.
Table 1
Demographic characteristics of patients and controls.
N Mean Age± SD Median Age Min. – Max.
PEXS 103 77.4 ± 8.1 78 54–96
Female 73 77.3 ± 8.3 78 56–96
Male 30 77.7 ± 7.9 78.5 54–88
Control 106 77.9 ± 7.7 78 53–94
Female 76 77.8 ± 7.7 78 57–94
Male 30 78.1 ± 7.9 79.5 53–88
PEXS; pseudoexfoliation syndrome, N; number of subjects, SD; standard deviation.
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3. Results
In search of SNPs associated with PEXS in a Polish population, a
cost-eﬀective GWAS using a pooled-DNA sample was conducted, using
10-sample pools of DNA obtained from 100 patients with PEXS without
glaucoma (70 females and 30 males; median age 78; mean age
77.0 ± 7.7) and 100 perfectly sex- and age-matched control subjects
(70 females and 30 males; median age 78; mean age 77.2 ± 7.2).
There were no statistically signiﬁcant diﬀerences between the two
groups regarding visual acuity, IOP, iridocorneal angle width, cup-disk
ratio, quantitative perimetry parameters, and quantitative OCT para-
meters for the optic nerve head (Table S2).
3.1. Genotyping
The susceptibility loci for PEXS revealed by pooled-DNA GWAS
were selected for further validation in individual samples. Our previous
observations (Ostrowski et al., 2016; Paziewska et al., 2017) and other
reports (Krumbiegel et al., 2011) indicated that, in the case of relatively
small patient cohorts, when the statistical power to detect SNPs at
standard genome-wide signiﬁcance level (p < 5×10−8) is in-
suﬃcient, a focus on the loci forming blocks of associated SNPs that
remained in a close distance (less than 30 kb between adjacent SNPs) is
a successful approach for SNP selection, even though the association
occurs at lower than standard signiﬁcance level. Based on such an ap-
proach, 15 independent loci were identiﬁed and, from each of them,
one index SNP, associated with PEXS at p < 10−4, was selected for
further validation. Among the selected loci, eight were represented by
blocks of at least 10 SNPs associating at p < 5×10−3. The remaining
loci were represented by fewer than 10 SNPs in a block, but at least two
of them associated at p < 10−4.
All selected SNPs were subsequently examined by TaqMan geno-
typing using individual DNA samples from both PEXS (N=103) and
control (N=106) groups (Table 1). As shown in Table 2, 14 of the
analyzed SNPs exhibited diﬀerences (p < .05) in allele frequency be-
tween the PEXS and control groups and 12 of them remained signiﬁcant
after adjustment for multiple testing (p < 3.33×10−3). In addition,
the genotype frequencies of all but two of these SNPs (rs7085835 and
rs72769818) were signiﬁcantly associated with PEXS (Table 2). The
strongest association was observed for a previously identiﬁed
(Thorleifsson et al., 2007) SNP, rs2165241 in LOXL1 (p-values of
2.77×10−10 and 1.04× 10−10 for allele and genotype frequencies,
respectively). The other associations have not previously been reported.
Among them, the ﬁnding with the strongest signiﬁcance was for
rs1852211 in CD80 (p=6.95×10−5). The next seven SNPs revealed
associations at p≤ 9.15×10−4.
The minor allele (MA) of ﬁve SNPs was associated with an increased
risk of PEXS, while that of the remaining nine SNPs showed a protective
eﬀect (Table 2). The eﬀect size of all identiﬁed susceptibility loci was
relatively substantial (OR≥ 2 or≤ 0.5), which can be explained by the
limited statistical power of our GWAS due to the rather small number of
patients in the cohort. Considering the most favorable SNP population
frequency of 0.5, our GWAS reached a power ranging from 65% to 86%
to detect an eﬀect size of OR from 2.0 to 2.5, respectively (Table S1).
For more typical MA frequency of 0.3 and OR equal 1.4 study power
was 18%, making it signiﬁcantly underpowered for such detection. The
strongest eﬀect was observed for the SNP rs10888255, a nonsynon-
ymous variant in exon 1 of the OR11L1 gene (OR=0.21, 95% CI
0.08–0.051, p=3.97×10−4). Nine other SNPs were also located
within gene regions: one in an exon (rs16855789 in TNIK), one in a 3′-
untranslated region (rs12442768 in FMN1), and seven in introns
(Table 2). The remaining four SNPs were at intergenic locations (4q26,
5q34, 10p13, and 13q21).
3.2. Prediction modeling
To evaluate the diagnostic power of the selected SNPs for PEXS, a
prediction model was developed and parameters describing the accu-
racy of prediction were calculated, in accordance with a previously
described approach (Pośpiech et al., 2015, 2012; Walsh et al., 2011).
Multivariate binary logistic regression analysis enabled the selection of
10 signiﬁcant SNPs (p< .05) after controlling for the eﬀects of all of the
tested DNA variants. The selected SNPs were found to explain nearly
69% of the total risk of PEXS development, as assessed using the Na-
gelkerke pseudo-R2 statistic (Table 3). Among the remaining ﬁve SNPs,
the associations of three variants were also insigniﬁcant after correcting
for multiple testing, in the allele and/or genotype frequency analyses
(Table 2).
SNPs signiﬁcant in the multivariate logistic regression analysis were
ranked according to their p-value and sequentially introduced into the
prediction model. The genetic variants that improved the overall ac-
curacy of prediction by increasing the AUC parameter by at least 0.01
were chosen for the ﬁnal model, which consisted of eight SNPs:
rs2165241 (LOXL1), rs13117637 (SORBS2), rs2058527 (RBFOX1),
rs1537443 (13q21), rs72769818 (RNF180), rs1852211 (CD80),
rs12442768 (FMN1), and rs1375559 (CADM2) (Table 3). As expected,
the SNP rs2165241 in LOXL1 showed the strongest independent eﬀect
on the risk of PEXS development (OR=0.03, 95% CI 0.01–0.11,
p=1.87× 10−8), although the nonrisk allele C was the MA in our
study (46% of controls). A strong protective eﬀect was also exhibited by
four other variants: rs2058527-T (RBFOX1), rs1537443-T (13q21),
rs72769818-A (RNF180), and rs1852211-A (CD80). According to the
signiﬁcance of the eﬀect size, rs13117637-A (SORBS2) had the stron-
gest inﬂuence, after the LOXL1 variant, on the predictive accuracy of
PEXS (AUC change equal to 0.074). The direction of the eﬀects of all
variants was in agreement with those observed in the allelic association
analysis.
Next, the accuracy prediction parameters calculated for the 8-SNP
model were compared with those obtained for the model consisting of
only the well-known PEXS risk variant rs2165241 (LOXL1) (Table 4).
The overall accuracy expressed by the AUC value increased from 0.672
for rs2165241 alone to 0.890 when the 8-SNP prediction model was
applied. Similarly, sensitivity of PEXS prediction increased from 68.7%
to 78.8% and speciﬁcity increased slightly from 79.8% to 80.9%, when
comparing the 1-SNP and 8-SNP models, respectively. When a 70%
probability threshold was applied to the 8-SNP prediction model, the
prediction accuracy of the model improved, increasing the sensitivity of
PEXS prediction to 88% and the speciﬁcity to 81.8% (Table 4). How-
ever, inconclusive results were obtained at the level of 21.2%, which
means that, in 41 of the 193 surveyed individuals, the result of the
predictive analysis could not be resolved.
4. Discussion
Considering that PEXG has a more rapid and severe clinical course,
as well as more frequent need for surgery, compared with other forms
of OAG (Ritch, 2001), an early diagnosis of PEXS with subsequent en-
hanced surveillance would be beneﬁcial for patients suﬀering from this
disease. An early diagnosis of PEXS is also crucial for reducing the
number of complications related to diﬀerent ophthalmic surgical in-
terventions, including cataract surgery, which occur more frequently in
patients with this syndrome (Conway et al., 2004; Merkur et al., 2001).
The knowledge of genetic variants associated with PEXS susceptibility
could help in diagnosing this disease in its early stages. However, the
genetic background of PEXS is still poorly understood. To explore new
associations of genetic variants across the entire genome among Polish
patients with PEXS, we conducted pooling-DNA-based GWAS with
subsequent genotyping of selected SNPs in individual DNA samples.
Besides the obvious great economical advantage of pooling-DNA
approach (allelotyping), it has also several limitations. First of all, it
K. Zagajewska et al. Experimental Eye Research 168 (2018) 138–148
141
allows only for estimation of the mean allele frequencies of the pooled-
DNA samples, what introduces limit on the relative allele frequency
(RAF) diﬀerences that can be detected. Although, allelotyping was
shown to reliably detect SNPs with large or moderate genetic eﬀects
(Gaj et al., 2012; Pearson et al., 2007; Schrauwen et al., 2009), it needs
to be considered that associations with the lowest RAF diﬀerences may
be masked due to the pooling-speciﬁc error. The pooling-speciﬁc error
of the RAF is in particular high for the alleles with low MA frequency,
but it is lower when RAF values for two groups of pools are compared,
as in the case-control studies (Macgregor et al., 2008; Teumer et al.,
2013). The next limitation of allolotyping is that adjusting for popula-
tion stratiﬁcation is practically impossible after DNA pooling, thus for
such an approach little or no stratiﬁcation should exist or pools should
be appropriately designed in advance based on the knowledge of pos-
sible covariates. The more covariates will be taken into account when
designing separate pools, the less data will be lost compared to in-
dividual genotyping.
One possible reason for discrepancies among reported results of
association studies is misclassiﬁcation of case or control individuals,
which can reduce the power of a study as well as bias the results toward
no association (Pearson and Manolio, 2008). Especially for smaller
cohorts, precise diagnostic and exclusion criteria must be employed to
minimize misclassiﬁcation error and obtain the most homogeneous
groups possible for both cases and controls. To meet this requirement in
our GWAS, we have made a huge eﬀort to rigorously select patients
with pure PEXS, without any symptoms of glaucoma, what substantially
increased the homogeneity of the case cohort. In addition, the PEXS and
control groups were exactly age- and gender-matched (Table 1).
Moreover, relatively old individuals (mean age of nearly 78 years) were
enrolled in this study, which is considered to be an advantage in cases
of late-onset disease, reducing the likelihood of the eventual develop-
ment of PEXS among control individuals and PEXG among PEXS pa-
tients.
However, we were fully aware that the sample size of 200 subjects is
Table 2
The validation analysis of GWAS-selected SNPs allelic and genotypic association with PEXS.
dbSNP IDa Regionb Allele frequency (%) OR (95% CI) p-value Genotype frequency (%) OR (95% CI) p-value
MA MAFc Control PEXS Genotype Control PEXS
rs10888255 1q44
OR11L1
exon 1 (R171P)
C 0.130 27 (12.7) 6 (2.9) 0.21 (0.08-0.51) 3.97E-04 CC
CG
GG
1 (0.9)
25 (23.6)
80 (75.5)
0
6 (5.8)
97 (94.2)
–
0.20 (0.08-0.51)
5.25 (2.06-13.39)
8.10E-04
rs1852211 3q13.33
CD80
intron 2
A 0.161 47 (22.2) 16 (7.8) 0.30 (0,16–0.54) 6.95E-05 AA
AG
GG
7 (6.6)
33 (31.1)
66 (62.3)
2 (1.9)
12 (11.7)
89 (86.4)
0.28 (0.06-1.38)
0.29 (0.14-0.60)
3.85 (1.94-7.66)
3.44E-04
rs16855789 3q26.2
TNIK
exon 23 (synon.)
A 0.900 12 (5.7) 29 (14.4) 2.79 (1.38-5.64) 5.17E-03 AA
AG
GG
0
12 (11.3)
94 (88.7)
2 (2.0)
25 (24.8)
74 (73.3)
–
2.58 (1.21-5.46)
0.35 (0.17-0.74)
1.21E-02
rs1375559 3p12.1
CADM2
intron 2
T 0.293 56 (26.7) 87 (42.6) 2.04 (1.35-3.09) 9.15E-04 TT
CT
CC
9 (8.6)
38 (36.2)
58 (55.2)
17 (16.7)
53 (52.0)
32 (31.4)
2.13 (0.90-5.04)
1.91 (1.09–3.33)
0.37 (0.21–0.65)
2.03E-03
rs13117637 4q35.1
SORBS2
intron 30
A 0.521 85 (30.1) 118 (57.8) 2.05 (1.39-3.03) 4.28E-04 AA
AG
GG
19 (17.9)
47 (44.3)
40 (37.7)
33 (32.4)
52 (51.0)
17 (16.7)
2.19 (1.15-4.18)
1.31 (0.76-2.25)
0.33 (0.17-0.63)
1.34E-03
rs1352495 4q26
intergenic
C 0.429 104 (49.1) 68 (33.0) 0.51 (0.34-0.76) 1.22E-03 CC
CT
TT
24 (22.6)
56 (52.8)
26 (24.5)
10 (9.7)
48 (46.6)
45 (43.7)
0.37 (0.17-0.81)
0.78 (0.45-1.34)
2.39 (1.32-4.30)
3.31E-03
rs7730762 5q34
intergenic
A 0.058 15 (7.1) 41 (19.9) 3.26 (1.74-6.11) 2.11E-04 AA
AG
GG
0
15 (14.2)
91 (85.8)
3 (2.9)
35 (34.0)
65 (63.1)
–
3.12 (1.58-6.17)
0.28 (0.14-0.55)
4.78E-04
rs72769818 5q12.3
RNF180
intron 1
A 0.090 29 (13.9) 10 (4.9) 0.32 (0.15-0.67) 3.02E-03 AA
AG
GG
0
29 (27.9)
75 (72.1)
0
10 (9.8)
92 (90.2)
–
0.28 (0.13-0.61)
3.56 (1.63-7.77)
NaN
rs3798793 6q23.2
VNN1
intron 2
T 0.634 96 (45.3) 111 (53.9) 1.41 (0.96-2.07) 9.68E-02 TT
CT
CC
21 (19.8)
54 (50.9)
31 (29.2)
26 (25.2)
59 (57.3)
18 (17.5)
1.37 (0.71-2.62)
1.29 (0.75–2.23)
0.51 (0.27–0.99)
1.25E-01
rs7085835 10p13
intergenic
T 0.123 25 (11.8) 7 (3.4) 0.26 (0.11-0.62) 2.34E-03 TT
CT
CC
1 (0.9)
23 (21.7)
82 (77.4)
0
7 (6.8)
96 (93.2)
–
0.26 (0.11-0.64)
4.01 (1.65-9.79)
5.01E-03
rs1537443 13q21.1
intergenic
T 0.101 28 (14.1) 7 (3.5) 0.22 (0.09-0.51) 3.17E-04 TT
CT
CC
1 (1.0)
26 (26.3)
72 (72.7)
0
7 (6.9)
94 (93.1)
–
0.21 (0.09-0.51)
5.04 (2.08-12.22)
6.00E-04
rs9518579 13q33.1
FGF14
intron 4
C 0.410 106 (50.0) 65 (32.2) 0.47 (0.32-0.71) 3.42E-04 CC
CT
TT
28 (26.4)
50 (47.2)
28 (26.4)
11 (10.9)
43 (42.6)
47 (46.5)
0.34 (0.16-0.73)
0.83 (0.48-1.44)
2.42 (1.35-4.34)
1.80E-03
rs2165241 15q24.1
LOXL1
intron 1
C 0.713 98 (46.2) 35 (17.0) 0.24 (0.15-0.37) 2.77E-10 CC
CT
TT
16 (15.1)
66 (62.3)
24 (22.6)
1 (1.0)
33 (32.0)
69 (67.0)
0.06 (0.01-0.42)
0.29 (0.16-0.51)
6.93 (3.76-12.8)
1.04E-10
rs12442768 15q13.3
FMN1
UTR-3
C 0.102 33 (15.9) 56 (27.5) 2.01 (1.24-3.25) 6.19E-03 CC
AC
AA
1 (1.0)
31 (29.8)
72 (69.2)
4 (3.9)
48 (47.1)
50 (49.0)
4.20 (0.46-38.27)
2.09 (1.18-3.71)
0.43 (0.24-0.76)
9.06E-03
rs2058527 16p13.3
RBFOX1
intron 3
T 0.243 62 (29.2) 31 (15.0) 0.43 (0.26-0.69) 7.48E-04 TT
GT
GG
11 (10.4)
40 (37.7)
55 (51.9)
1 (1.0)
29 (28.2)
73 (70.9)
0.08 (0.01-0.67)
0.65 (0.36-1.16)
2.26 (1.27-3.99)
1.86E-03
Allelic frequencies of all studied SNPs were in Hardy-Weinberg equilibrium. Bold denotes signiﬁcant association after multiple testing adjustment (15 SNPs; p < 3.33E-03). MA; minor
allele, MAF; MA frequency, PEXS; pseudoexfoliation syndrome, OR; odds ratio, CI; conﬁdence interval.
a /SNP identiﬁer based on NCBI SNP database (http://www.ncbi.nlm.nih.gov/snp/).
b /NCBI ID of genes localized in proximity to the SNPs of interest (http://hapmap.ncbi.nlm.nih.gov/).
c /MAF based on NCBI SNP database (https://www.ncbi.nlm.nih.gov/snp/).
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rather small, considering GWAS, hardly allowing to achieve associa-
tions at the generally accepted level of genome-wide signiﬁcance
(p < 5×10−8). Therefore, we have adopted the modiﬁed method of
selecting SNPs for validation, based more on biological criteria than
purely statistical. Assuming that each associating SNP is usually not
independent of neighborhood, we focused on loci represented by blocks
of SNPs associated with a disease at p < 5×10−3, remaining in a
close distance of less than 30 kb between adjacent SNPs. Then an index
SNP, associating at the highest level of signiﬁcance, was selected for
further validation as representative of each of these loci. Such an ap-
proach was successfully introduced by us in the recently published
studies (Ostrowski et al., 2016; Paziewska et al., 2017), indicating that
selection of index SNPs according to allele linkage disequilibrium (LD)
reduces the number of false-positive genome-wide associations and
allows for discovery of new associations.
Altogether, the applied approach allowed us to detect several loci
that showed marked diﬀerences in allelic frequencies between patients
with PEXS and controls, including the LOXL1 locus, which proved the
validity of the obtained data. None of the remaining signiﬁcant SNPs
has previously been reported to be associated with PEXS.
4.1. LOXL1 association
In our microarray analysis, the LOXL1 locus was represented by a
cluster of 20 SNPs associating with PEXS at p < 5×10−3, with in-
tervals of less than 30 kb between any two adjacent SNPs. An associa-
tion of two SNPs (rs2165241 and rs4886778) with PEXS was at the
level of p < 2.93×10−7. The transcriptionally relevant SNP
rs16958477 within the promoter region of LOXL1 (Fan et al., 2011),
although included in the selected cluster, showed a weaker association
(p=4×10−3). In addition, known PEXS susceptibility SNPs in coding
regions, rs3825942, rs1048661, and rs41435250 (Guadarrama-Vallejo
et al., 2013; Thorleifsson et al., 2007), as well as the rare nonsynon-
ymous protective variant rs201011613, which showed signiﬁcant as-
sociation in single-variant analysis in just published studies (Aung et al.,
2017), are not included in the Illumina microarray used in the current
study. For further validation in individual samples, rs2165241 was
chosen as the index SNP of the LOXL1 locus. The allelic frequency of
this variant demonstrated the strongest association with the risk of
PEXS (p=2.77× 10−10) among all of the 12 SNPs that remained
signiﬁcant after correcting for multiple hypothesis testing (Table 2).
Similarly to a previous replication study on LOXL1 variants among 36
PEXS/PEXG Polish patients (Malukiewicz et al., 2011), the risk allele T
of this SNP was more common than allele C, not only among PEXS
patients (83% and 87.5%, respectively) but also in the control group
(54% and 65%, respectively). The eﬀect of allele T (OR=4.2, 95% CI
2.67–6.61, p=2.77× 10−10) in our study was consistent with that
identiﬁed in an early GWAS (OR=3.18, 95% CI 2.12–4.76,
p=1.9× 10−8) (Thorleifsson et al., 2007) or by sequencing the entire
LOXL1 gene and subsequent association analysis in Spanish individuals
(OR=4.74, 95% CI 2.72–8.28, p=6.3×10−16), in which rs2165241
exhibited the strongest disease association among 49 SNPs showing
signiﬁcant diﬀerences in allelic frequencies between cases and controls
(Álvarez et al., 2015). In addition, in two recent meta-analyses,
rs2165241 showed a stronger association with PEXS/PEXG than both
rs3825942 and rs1048661 SNPs within coding regions (Founti et al.,
2015; Tang et al., 2014). It was suggested, however, that the only
reason for this strong association is that allele T of rs2165241 eﬀec-
tively tagged the high-risk GG haplotype of the coding sequence var-
iants (Thorleifsson et al., 2007).
Ethnicity-based diﬀerences were observed in the association of
diﬀerent LOXL1 variants with PEXS/PEXG. A meta-analysis including
39 independent studies showed that rs2165241-C was a protective al-
lele for the disease in Caucasians (13 studies; OR=0.31), in ac-
cordance with our ﬁndings, but was a risk allele in Japanese (3 studies;
OR=7.49) and Koreans (2 studies; OR=6.63) (Founti et al., 2015). In
addition, for the SNPs rs1048661 (Founti et al., 2015) and rs4886776
(Aung et al., 2015), the direction of the association in the non-Japanese
was opposite to that seen in the Japanese, suggesting that other po-
pulation-based genetic factors may modify the eﬀect of LOXL1 variants.
In addition, the possibility of LOXL1 intragenic epistatic eﬀects was
proposed, like the one between newly identiﬁed synonymous (A310A)
exon 1 risk variant rs41435250 and rs2165241 in Mexicans
(Guadarrama-Vallejo et al., 2013); however, this has yet to be con-
ﬁrmed.
4.2. Possible functional associations with PEXS
Apart from rs2165241 in LOXL1, nine additional identiﬁed SNPs
were within gene regions (Table 2). Although it is rather unlikely that
the associated polymorphisms are directly causative, the functions of
the proteins encoded by these genes suggest that they may be relevant
to PEXS development. The strongest new association
(p=6.95× 10−5) reported in the current study was observed for
rs1852211, which is located within an intron in CD80. The B7 genes
(CD80 and CD86) were suggested to play a protective role against the
development of optic neuropathy in patients with Graves’ disease and a
two-locus model was proposed to predict the risk of optic nerve damage
(Liao et al., 2011). Both CD80 and CD86 are membrane receptors on
antigen-presenting cells, activated by the binding of CD28 or cytotoxic
Table 3
The results of multivariate binary logistic regression analysis.
dbSNP IDa OR (95% CI) p-value R2 b AUCc AUC change
rs2165241 0.03 (0.01-0.11) 1.87× 10−8 0.302 0.672 -
rs13117637 6.74 (2.29-19.86) .001 0.394 0.746 0.074
rs2058527 0.22 (0.08-0.59) .002 0.448 0.782 0.036
rs1537443 0.13 (0.04-0.49) .003 0.494 0.814 0.032
rs72769818 0.15 (0.04-0.52) .003 0.543 0.831 0.017
rs1852211 0.19 (0.06-0.60) .005 0.585 0.854 0.023
rs12442768 3.79 (1.46-9.85) .006 0.620 0.873 0.019
rs1375559 3.55 (1.40-9.00) .008 0.644 0.890 0.017
rs7730762 3.90 (1.30-11.71) .015 0.667 0.892 0.002
rs1352495 0.28 (0.10-0.79) .016 0.689 0.898 0.006
Ten signiﬁcant SNPs are presented (p < .05), ranked according to their signiﬁcance p-
value, starting from the most signiﬁcant association of LOXL1 gene variant. SNPs pro-
viding area under the ROC curve (AUC) parameter change by≥ 0.01 were marked with
bold and included in the ﬁnal 8-SNPs prediction model. Odds ratios (ORs) were calculated
for the minor alleles coded in a dominant way (homozygotes of minor allele were com-
bined with heterozygotes). CI; conﬁdence interval.
a SNP identiﬁer based on NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/).
b Nagelkerke pseudo-R2 value calculated after sequential implementation of the ranked
SNPs.
c AUC value calculated after sequential implementation of the ranked SNPs.
Table 4
Risk prediction based on 1-SNP (LOXL1) or 8-SNPs models.
Prediction
parameters
Probability
threshold
rs2165241-
prediction model
8-SNPs
prediction model
AUC - 0.672 [SE 0.041] 0.890 [SE 0.022]
50%
Sensitivity 68.7% [68/99] 78.8% [78/99]
Speciﬁcity 79.8% [75/94] 80.9% [76/94]
PPV 78.2% [68/87] 81.3% [78/96]
NPV 70.8% [75/106] 78.4% [76/97]
70%
Sensitivity 73.9% [68/92] 88.0% [66/75]
Speciﬁcity 68.9% [42/61] 81.8% [63/77]
PPV 78.2% [68/87] 82.5% [66/80]
NPV 63.6% [42/66] 87.5% [63/72]
Inconclusive 20.7% [40/193] 21.2% [41/193]
AUC; area under the ROC curve, SE; standard error, PPV; positive predictive value, NPV;
negative predictive value.
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T-lymphocyte-associated (CTLA)-4 protein. Polymorphism within the
genes belonging to the CD80/CD86-CD28/CTLA-4 pathway may
modify the risk of multiple sclerosis and the interaction between certain
variants of these genes was found to inﬂuence the age at disease onset
(Wagner et al., 2015).
The strongest eﬀect on PEXS susceptibility was identiﬁed for the
SNP rs10888255, a nonsynonymous variant (R171P) in the ﬁrst exon of
an olfactory receptor (OR11L1) gene, of which the MA (allele C) fre-
quency was signiﬁcantly lower (OR=0.21, 95% CI 0.08–0.51) in PEXS
patients than in controls. Olfactory receptors (OlfRs) represent the
largest class of G-protein-coupled receptors, which share a seven-
transmembrane domain structure with many neurotransmitter and
hormone receptors. They are typically considered to be detectors and
transducers of signals from odorant molecules in the nose to the brain.
However, OlfRs are also localized in many other organs outside the
nasal cavity, playing diﬀerent tissue-speciﬁc functions distinct from the
perception of odors (Ferrer et al., 2016). Ectopic expression of OlfRs
was recognized in neurons of the central nervous system and its al-
teration was identiﬁed in several neurodegenerative and mental dis-
orders. Recently, a number of species of OlfRs were found to be ex-
pressed in murine corneal epithelium, suggesting that they play a role
in sensing the ocular environment and maintaining homeostasis of the
eye (Pronin et al., 2014). Speciﬁcally, it was speculated that Olfr558,
which has a close human homolog, OR51E1, is involved in regulation of
the arteriole diameter and blood ﬂow in the choroid, aﬀecting the
amount of oxygen and nourishment provided to the outer layers of the
retina.
The strict regulation of actin cytoskeleton remodeling is critical for
the proper formation of neurites during brain development. This is
controlled by multiple signaling pathways, acting as the cascades of
signal transduction through a variety of regulatory proteins. Formin 1,
the protein encoded by the FMN1 gene, is an important regulator of
actin ﬁbers and microtubule dynamics during cell division, cell mi-
gration, and development and is involved in the formation of adherens
junctions (Dettenhofer et al., 2008). Through the neurogenin 3 sig-
naling pathway, it mediates the induction of dendritogenesis and sy-
naptogenesis in mouse hippocampal neurons and can modulate actin-
based synaptic structures (Simon-Areces et al., 2011). It also partici-
pates in the control of neuronal morphology and diﬀerentiation, as well
as neuronal and axonal mobility. Formin 1 is involved in glutamatergic
synaptic transmission, being connected mainly with excitatory post-
synaptic potential. Its dysfunction has been implicated in early-onset
obsessive-compulsive disorder (Cappi et al., 2014). The other actin
cytoskeleton-related protein is ArgBP2, a small adaptor protein that
binds c-Arg and c-Abl non-receptor-type tyrosine kinases, encoded by
the sorbin and SH3 domain-containing 2 (SORBS2) gene. SORBS2 is
widely expressed in human tissues at actin stress ﬁbers and the nucleus
(Kioka et al., 2002). ArgBP2 is involved in the assembly of signaling
complexes that play a role in the formation and stabilization of focal
contacts. Among its important binding partners is vinculin, an actin-
binding cytoskeletal protein associated with cell–ECM and cell–cell
junctions (Kioka et al., 2002), and Fat1 protein, an atypical cadherin
expressed at intercellular junctions, lamellipodia, and ﬁlopodia, the
inactivation of which leads to defective neuronal development (Braun
et al., 2016). Neural ArgBP2 splicing variant, exclusively expressed in
the brain, is colocalized with F-actin in neural dendritic cones and
spines and plays an important role in neuronal dendrite development
and excitatory synaptic transmission (Zhang et al., 2016).
The signaling pathways that are involved in the control of neur-
itogenesis are themselves subject to control, mostly by the ubiquitina-
tion and proteasomal degradation of their key regulatory elements.
Especially important in this context is inhibition of the formation of
new neurites once the ﬁnal neural network has been established in the
mature brain. TRAF2 and NCK-interacting kinase (TNIK) is a serine/
threonine kinase that modulates actin dynamics. Overexpression of
wild-type TNIK results in the disruption of F-actin structure and cell
spreading (Taira et al., 2004). TNIK is a speciﬁc eﬀector of the small
GTPase RAP2, known as a negative regulator of dendritogenesis
(Kawabe et al., 2010). Interaction of TNIK with RAP2 is essential for the
binding of NEDD4-1 ubiquitin E3 ligase to a signaling complex, which
regulates neural dendrite extension and arborization. Ubiquitination by
NEDD4-1 inhibits RAP2 function, leading to the reduction of TNIK ac-
tivity and promotion of dendrite growth. TNIK is highly expressed in
the brain and TNIK mRNA was shown to be upregulated in the dorso-
lateral prefrontal cortex of patients with schizophrenia (Glatt et al.,
2005). In turn, RNF180 is a RING ﬁnger membrane-bound E3 ubiquitin
ligase, tail-anchored to the endoplasmic reticulum. It is expressed in
several adult tissues and in immature brain and lens (Ogawa et al.,
2008). RNF180 interacts with the transcription factor ZIC2 and together
with the E2 ubiquitin-conjugating enzyme UBE2E1 leads to ZIC2 ubi-
quitination and proteasomal degradation. Mouse Zic2 was found to be
expressed in retinal ganglion cells with an uncrossed trajectory, at the
time when these cells grew from the ventrotemporal retina toward the
optic chiasm, and was necessary to regulate axon repulsion by cues at
the optic chiasm midline (Herrera et al., 2003).
Several further associations identiﬁed in the current study are in
some way related to nervous system development and function, es-
sentially with synapse organization and synaptic transmission.
Alterations in a gene encoding an RNA-binding protein, fox-1 homolog
(RBFOX1), were reported in a range of neurobehavioral phenotypes
including epilepsy, autism, and mental retardation (Bill et al., 2013;
Zhou et al., 2014). By interaction with ataxin-2, the encoded protein
may contribute to spinocerebellar ataxia type 2. RBFOX1 is considered
a key regulator of the expression of large gene networks during neu-
ronal development and maturation, acting on their alternative splicing
or transcription programs. It plays a role in the homeostatic control of
neuronal excitation upon exposure to secreted neurotransmitters
(Gehman et al., 2011). It is hypothesized that the regulatory activity of
RBFOX1 may be stimulated as an adaptive response to environmental
or cellular stressors; thus, variation in this gene could modify disease
risk under certain conditions (Bill et al., 2013). Besides the brain, heart,
and muscle tissues, RBFOX1 is expressed in the retina (Bitel et al., 2011)
and its SNP variants have been implicated in refractive error
(Stambolian et al., 2013) and myopia (Kiefer et al., 2013). Cell adhesion
molecule 2 (CADM2) is involved in synapse organization and main-
taining synaptic circuitry of the central nervous system (Frei et al.,
2014). CADM2 is almost exclusively expressed in the brain and retina
(Postel et al., 2013). An intronic SNP, rs17518584, was found to sig-
niﬁcantly inﬂuence CADM2 expression levels in the brain, especially in
the frontal and anterior cingulated cortex (Ibrahim-Verbaas et al.,
2016). The CADM2 protein is involved in glutamate neurosignaling
pathways, gamma-aminobutyric acid (GABA) transport, and neuron
cell–cell adhesion. It is positively coexpressed with many members of
the voltage-gated K+ channel group. GWASs showed an association of
CADM2 with general cognitive functions and educational attainment
(Davies et al., 2016; Ibrahim-Verbaas et al., 2016).
Genetic variations in the ﬁbroblast growth factor 14 (FGF14) gene
have been associated with familial spinocerebellar ataxia 27 as well as
schizophrenia and depression (Xiao et al., 2013). It is expressed
throughout the nervous system, but the protein that it encodes is pre-
ferentially localized in the axon initial segment, which is critical for the
initiation of action potentials (Xiao et al., 2013). FGF14 directly in-
teracts with the voltage-gated Na+ channels and mutation that disrupts
this interaction results in reduced expression of the Na+ channel α
subunit at the axon initial segment and impaired neuronal excitability
(Laezza et al., 2007). Furthermore, FGF14 is a potent regulator of the
presynaptic P/Q-type voltage-gated Ca2+ channel (Cav2.1) and sy-
naptic transmission in cerebellar neurons (Yan et al., 2013). The neu-
ronal ion channels help to control the release of neurotransmitters and
are essential for communication between neurons in the brain. It is
considered that Cav2.1 channels are also involved in the survival of
neuronal cells and their plasticity.
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The biological activities of both CACNA1A and CNTNAP2 genes,
common variants of which were shown by previously conducted
GWASs to be associated with PEXS/PEXG susceptibility (Aung et al.,
2015; Krumbiegel et al., 2011), ﬁt well with the processes and signaling
pathways in which the genes identiﬁed in the current study are in-
volved. For example, mutations in the CACNA1A gene, encoding the
α1A subunit of Cav2.1 in neurons, have been implicated in spinocer-
ebellar ataxia type 6, episodic ataxia type 2, hemiplegic migraine, and
epilepsy (Tantsis et al., 2016). The G allele of the SNP rs4926244, as-
sociated with PEXS/PEXG at OR ≤ 1.29 in both GWAS and validation
stages, was modestly correlated with lower CACNA1A mRNA levels in
peripheral blood cells (Aung et al., 2015). It was hypothesized that
altered expression and function of Ca2+ channels could inﬂuence the
risk of PEX material aggregation by altering the concentration of Ca2+
ions. In the current study, however, none of the common CACNA1A
variants showed evidence for an association with PEXS. The most likely
explanation for this discrepancy is that the size of the patient cohort in
our GWAS made it statistically underpowered to detect associations at
an OR lower than 2, which was the case for the OR of the CACNA1A
variant.
The CNTNAP2 gene has also been implicated in neuropsychiatric
disorders, including epilepsy, schizophrenia, autism, and mental re-
tardation (Lu et al., 2016). CNTNAP2 is a large multi-domain trans-
membrane cell adhesion molecule at axo-glial and synaptic contacts.
Speciﬁcally, it is localized at the juxtaparanodes of myelinated axons.
As part of an extensive protein network, it mediates the traﬃcking and
clustering of Na+ and K+ channels for eﬃcient action potential pro-
pagation (Faivre-Sarrailh and Devaux, 2013). It is essential for main-
taining normal synaptic transmission, neural migration, and synapse
development (Lu et al., 2016; Peñagarikano et al., 2011). CNTNAP2
was found to be expressed in all human ocular tissues, particularly in
the retina (Krumbiegel et al., 2011). It is speculated that the interaction
of CNTNAP2 with cytoskeletal proteins is crucial for membrane stabi-
lization and that alterations in membrane stabilization or ion channel
function may contribute to abnormal PEX aggregate formation. Al-
though both rs2107856 and rs2141388, the SNPs in CNTNAP2 most
signiﬁcantly associated with PEXS/PEXG (Krumbiegel et al., 2011), are
not included in the Illumina array, a block of 13 SNPs located in this
gene, with an interval of less than 30 kb between adjacent SNPs, and
associating with PEXS at p≤ 5×10−3 was identiﬁed in the current
study. However, none of these SNPs showed an association with PEXS
at p≤ 10−4 in order to be selected as an index SNP of this locus for
further validation. The most signiﬁcant association was observed for
rs6961110 (p=9.3× 10−4). Consistent with this, in a previous re-
plication study on 48 PEXS patients from a Polish population, no sig-
niﬁcant diﬀerences in allele frequencies were found for both rs2107856
and rs2141388 in CNTNAP2, compared to controls (Malukiewicz et al.,
2012).
From ﬁve lately identiﬁed new susceptibility variants (Aung et al.,
2017), one (rs3130283) is not represented in microarray data from Il-
lumina Human Omni2.5-Exome BeadChips, which we have been using.
The remaining four SNPs were not signiﬁcantly associated with PEXS in
our study. The only p-value< .1 was for SNP rs10072088 (SEMA6A;
p= .077). In close vicinity (± 50 kb) to this SNP, there were 22 var-
iants with p < .1 (the lowest p= .013). The strongest genetic eﬀect
observed for these ﬁve newly identiﬁed variants is OR=1.24. Thus,
not surprisingly none of them shows up signiﬁcant, considering the
statistical power of our study.
The evidence on the identiﬁed PEXS susceptibility genes presented
above suggests that nervous system development and maturation,
neuronal migration, synapse organization, and synaptic transmission,
as well as actin cytoskeleton remodeling and interaction between ECM
and cells, are possible processes that contribute to PEXS. In general, this
agrees with “protein sink model”, which assumes that weakening of the
blood-aqueous barrier and the leakage of serum proteins, inﬂammatory
mediators, and ECM components into aqueous humor is a key element
of the pathogenic process that eventually leads to aggregation and
precipitation of PEX material (Vazquez and Lee, 2014). In addition,
changes in ECM proteins and structural composition of the eye elastic
tissues can lead to increased IOP and mechanical damage to the optic
nerve.
Similarly, complex interaction between ECM, neuronal develop-
ment, and visual signals from the retina was suggested to underlie the
development of myopia, based on GWAS-identiﬁed associations invol-
ving the RBFOX1 and ZIC2 genes, among others (Kiefer et al., 2013). In
turn, TNIK-included gene regulatory networks related to cell migration,
cytoskeleton reorganization, development of forebrain structures, and
axonal connectivity were found to be involved in schizophrenia (Potkin
et al., 2010). On the other hand, increased production or reduced de-
gradation of ECM, inﬂammation, and oxidative stress were suggested to
contribute to the pathogenesis of PEXS, based on the presence of ECM
proteins and remodeling enzymes, complement proteins, cell adhesion
molecules, and stress response proteins in PEX material, as well as on
the altered expression of the genes encoding such proteins in the af-
fected ocular anterior segment tissues (Ovodenko et al., 2007;
Schlötzer-Schrehardt and Naumann, 2006; Zenkel and Schlötzer-
Schrehardt, 2014).
4.3. Prediction modeling
Multivariate regression analysis enabled us to select 10 SNPs that
have signiﬁcant independent eﬀects on PEXS, from the set of all 15
tested DNA variants. Associations of three excluded SNPs (rs3798793,
rs16855789, rs7085835) were also weak in the allele or genotype fre-
quency analysis. The eﬀects of the next two SNPs, rs10888255 in
OR11L1 and rs9518579 in FGF14, although strong in the allelic test,
were probably correlated with other included variants. Since none of
the remaining SNPs is located in the same LD block, an impact of in-
tergenic epistatic interactions or other epigenetic events is a possible
explanation of this inconsistency, but further studies are needed to
verify any such hypotheses. Among the selected SNPs, rs2165241 in
LOXL1 alone was found to explain 30% of the overall risk of developing
PEXS. An additional nine signiﬁcantly associated SNPs explained an-
other 39%, giving a total of 69% (Table 3).
It is beyond doubt that LOXL1 can be considered a major genetic
risk factor for PEXS, conferring 80–99% population attributable risk in
various cohorts (Challa, 2009; Thorleifsson et al., 2007). However, the
high prevalence of LOXL1 risk variants among control individuals and
the much lower proportion of the population developing a PEXS/PEXG
phenotype indicates that a genetic test for LOXL1 may be of limited
clinical use. Consistent with this, the estimated ability of the G allele of
two known SNPs in the LOXL1 coding region, rs3825942 and
rs1048661, to predict aﬀection status showed 100% and 95.7% sensi-
tivity and 3.1% and 13% speciﬁcity, respectively (Challa, 2009). Si-
milarly, rs3825942 indicated 100% sensitivity and 13.3% speciﬁcity in
a Polish population (Malukiewicz et al., 2011). In the same study, the T
allele of an intronic SNP rs2165241 indicated 87.5% sensitivity and
35% speciﬁcity in a diagnostic test for PEXS. In contrast, the C allele of
this variant in the 1-SNP risk prediction model developed in the current
study showed 69% sensitivity and 80% speciﬁcity. However, the overall
accuracy of prediction was rather low (AUC=0.672). The inclusion of
seven additional SNPs, apart from rs2165241, in the ﬁnal 8-SNP pre-
diction model increased the AUC value to 0.89. Assuming a 70%
probability threshold, which is more reasonable for diagnostic pur-
poses, the sensitivity of prediction increased by 14%, to 88%, and
speciﬁcity increased by 13%, to 82%; however 21% of the surveyed
individuals remained unclassiﬁed. Because of the limited number of
samples, 10-fold cross-validation was used for estimating the model
accuracy. However, the developed prediction model needs to be further
validated on a separate, unrelated testing set of samples.
In accordance with the estimated statistical power of our GWAS, all
identiﬁed PEXS susceptibility variants conferred risk with an OR≥ 2 or
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≤0.5. In this context, the following question arises: Why were SNP
associations with rather substantial eﬀects not discovered in the pre-
viously conducted GWASs on PEXS? The main diﬀerence among these
studies concerns the case cohorts. In the majority of studies carried out
to date, the case cohorts consisted of combined patients with either
PEXS or PEXG. To the best of our knowledge, the current study is the
ﬁrst conducted on such a large group of over 100 patients with clear
PEXS, without any symptoms of glaucoma. Given that most of the in-
cluded subjects were elderly, it cannot be ruled out that PEXS patients
in whom glaucoma has never developed or will appear at a later stage
are overrepresented in this study. Therefore, at least some of the
identiﬁed variants may be related to the prevention of the glaucoma-
tous process rather than to PEXS itself. Notably, for most of the sus-
ceptibility variants, the MA exhibited a strong protective eﬀect against
PEXS, which matches the assumption that other common variants can
modify the risk of PEXS development associated with LOXL1 risk var-
iants (Jonasson, 2009).
4.4. Conclusion
Several new common genetic variants associated with PEXS without
glaucoma in a Polish population were revealed by a GWAS of relatively
low statistical power, suggesting that there are still other unidentiﬁed
associations with a lower eﬀect size. For most of the discovered sus-
ceptibility SNPs, the MA was associated with a reduced risk of PEXS
development. Apart from the known LOXL1 variant rs2165241, nine
other SNPs located in gene regions were identiﬁed. The molecular
functions of the proteins encoded by these genes suggested that nervous
system development and maturation, neuronal migration, synapse or-
ganization, and synaptic transmission, as well as actin cytoskeleton
remodeling and interaction between ECM and cells, may contribute to
the development of PEXS or to inhibition or delay of its conversion to
glaucoma. The overall accuracy of the prediction model for PEXS,
consisting of eight discovered susceptibility variants, is 0.89. Several
lines of evidence suggest that this classiﬁer may allow patients with
PEXS but with a reduced risk of developing glaucoma to be dis-
tinguished. However, there is a need for future studies that replicate
these analyses in independent study groups.
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